HK1222182A1 - 三聚體抗原結合分子 - Google Patents

三聚體抗原結合分子

Info

Publication number
HK1222182A1
HK1222182A1 HK16110302.4A HK16110302A HK1222182A1 HK 1222182 A1 HK1222182 A1 HK 1222182A1 HK 16110302 A HK16110302 A HK 16110302A HK 1222182 A1 HK1222182 A1 HK 1222182A1
Authority
HK
Hong Kong
Prior art keywords
antigen binding
binding molecules
trimeric antigen
trimeric
molecules
Prior art date
Application number
HK16110302.4A
Other languages
English (en)
Inventor
Peter Bruenker
Koller Claudia Ferrara
Sandra Graurichards
Ekkehard Moessner
Pablo Umana
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1222182A1 publication Critical patent/HK1222182A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
HK16110302.4A 2013-05-07 2016-08-30 三聚體抗原結合分子 HK1222182A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166793 2013-05-07
PCT/EP2014/059030 WO2014180754A1 (en) 2013-05-07 2014-05-05 Trimeric antigen binding molecules

Publications (1)

Publication Number Publication Date
HK1222182A1 true HK1222182A1 (zh) 2017-06-23

Family

ID=48227070

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110302.4A HK1222182A1 (zh) 2013-05-07 2016-08-30 三聚體抗原結合分子

Country Status (10)

Country Link
US (1) US9975958B2 (zh)
EP (1) EP2994487B1 (zh)
JP (1) JP6618463B2 (zh)
KR (1) KR20160005345A (zh)
CN (1) CN105377893A (zh)
CA (1) CA2907597A1 (zh)
HK (1) HK1222182A1 (zh)
MX (1) MX2015014538A (zh)
RU (1) RU2015152077A (zh)
WO (1) WO2014180754A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
JP6810687B2 (ja) * 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法
MY191428A (en) 2014-11-14 2022-06-27 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
US10501552B2 (en) * 2015-01-26 2019-12-10 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
CN114751989A (zh) 2015-03-31 2022-07-15 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
EA201890041A1 (ru) 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP7034066B2 (ja) 2015-10-02 2022-03-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する二重特異性抗体
WO2017104796A1 (ja) * 2015-12-16 2017-06-22 国立大学法人 岡山大学 人工ｒｎａ制限酵素
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
JP2019205355A (ja) * 2016-09-30 2019-12-05 国立大学法人名古屋大学 分子改変体アディポネクチン及び分子改変体アディポネクチンを含む医薬組成物
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
BR112019017753A2 (pt) * 2017-04-04 2020-04-07 Hoffmann La Roche molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica
WO2018212556A1 (en) * 2017-05-16 2018-11-22 Cj Healthcare Corporation A method for purifying an antibody or an antibody fragment thereof using affinity chromatography
US11590219B2 (en) 2018-01-30 2023-02-28 Emory University Compositions and methods for promoting immune responses to human immunodeficiency virus
CN114409803B (zh) * 2020-12-31 2023-10-20 中国科学院微生物研究所 流感病毒三聚体亚单位疫苗及其应用
CN114409802B (zh) * 2020-12-31 2023-10-20 中国科学院微生物研究所 禽流感病毒三聚体亚单位疫苗及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US10183986B2 (en) * 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
CN102250254A (zh) * 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
US9409987B2 (en) * 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer

Also Published As

Publication number Publication date
CA2907597A1 (en) 2014-11-13
MX2015014538A (es) 2016-02-05
JP2016520055A (ja) 2016-07-11
US20160159917A1 (en) 2016-06-09
US9975958B2 (en) 2018-05-22
EP2994487A1 (en) 2016-03-16
CN105377893A (zh) 2016-03-02
KR20160005345A (ko) 2016-01-14
EP2994487B1 (en) 2019-10-09
WO2014180754A1 (en) 2014-11-13
RU2015152077A (ru) 2017-06-13
JP6618463B2 (ja) 2019-12-11

Similar Documents

Publication Publication Date Title
IL271102A (en) Antigen-binding molecules from bispecific t-cell activators
HK1222182A1 (zh) 三聚體抗原結合分子
HK1218425A1 (zh) 雙特異性 細胞活化抗原結合分子
HK1211299A1 (zh) 雙特異性 細胞活化性抗原結合分子
HK1224313A1 (zh) 抗體
HK1218551A1 (zh) 識別 的高親和力結合分子
IL240838A0 (en) Anti-3–lag binding proteins
LT2970449T (lt) Viengrandės surišančios molekulės, apimančios n galo abp
GB201308658D0 (en) Antibodies
GB201315487D0 (en) Antibodies
GB201315486D0 (en) Antibodies
SG11201604663SA (en) Cd44 binding peptides
GB201300706D0 (en) Antibody
ZA201507808B (en) Binding element
GB201302878D0 (en) Modified igG molecules
HK1220106A1 (zh) 壓縮元件
GB201314294D0 (en) Binding surfaces